Date	e:2022/8/1	6	
You	r Name: Qiong	g Chen	
Mar	nuscript Title: Incidence	and mortality of gastric	cancer in 2018 and their trends from 2010 to 2018 in Henan
Prov	vince, China: Results from a	provincial population-bas	sed cancer registry
Mar	nuscript number (if known):		
rela part to ti	ted to the content of your n ies whose interests may be	nanuscript. "Related" mea affected by the content o ecessarily indicate a bias.	relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a o so.
	following questions apply t nuscript only.	o the author's relationshi	ps/activities/interests as they relate to the current
to tl		nsion, you should declare	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive the manuscript.
	em #1 below, report all sup time frame for disclosure is		d in this manuscript without time limit. For all other items,
		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as	
		needed)	
		Time frame: Since the initi	al planning of the work
1	All support for the present	XNone	
	manuscript (e.g., funding,		
	provision of study materials, medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: pas	st 36 months
2	Grants or contracts from	X None	of 30 months
_	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	XNone	

Consulting fees

Payment or honoraria for	XNone	
lectures, presentations,		
speakers bureaus,		
	V Name	
•	x_None	
testimony		
	XNone	
meetings and/or travel		
	XNone	
pending		
Participation on a Data	XNone	
Safety Monitoring Board or		
Advisory Board		
Leadership or fiduciary role	X None	
1		
7		
	V None	
Stock or stock options	xNone	_
	XNone	
writing, gifts or other		
services		
Other financial or non-	XNone	
financial interests		
	speakers bureaus, manuscript writing or educational events Payment for expert testimony Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options Receipt of equipment, materials, drugs, medical writing, gifts or other services Other financial or non-	lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options Receipt of equipment, materials, drugs, medical writing, gifts or other services Other financial or non- X_None

None.		

Please place an "X" next to the following statement to indicate your agreement:

Date	e:2022/8/1	6	
You	r Name: Chen	Cheng	
Mar Prov	nuscript Title: Incidence rince, China: Results from a	e and mortality of gastric or provincial population-base	ancer in 2018 and their trends from 2010 to 2018 in Henan
Mar	nuscript number (if known):		
relat part to tr	ted to the content of your n ies whose interests may be	nanuscript. "Related" mea affected by the content of ecessarily indicate a bias.	relationships/activities/interests listed below that are ns any relation with for-profit or not-for-profit third f the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a so.
	following questions apply to uscript only.	o the author's relationship	os/activities/interests as they relate to the current
to th	-	nsion, you should declare	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive he manuscript.
	em #1 below, report all sup time frame for disclosure is	·	I in this manuscript without time limit. For all other items,
		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as	
		needed) Time frame: Since the initia	I planning of the work
1	All suppose for the present	I	n planning of the work
1	All support for the present manuscript (e.g., funding,	XNone	
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	XNone	
	any entity (if not indicated		
2	in item #1 above).	V N	
3	Royalties or licenses	XNone	

Consulting fees

Payment or honoraria for	XNone	
lectures, presentations,		
speakers bureaus,		
	V Name	
•	x_None	
testimony		
	XNone	
meetings and/or travel		
	XNone	
pending		
Participation on a Data	XNone	
Safety Monitoring Board or		
Advisory Board		
Leadership or fiduciary role	X None	
1		
7		
	V None	
Stock or stock options	xNone	_
	XNone	
writing, gifts or other		
services		
Other financial or non-	XNone	
financial interests		
	speakers bureaus, manuscript writing or educational events Payment for expert testimony Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options Receipt of equipment, materials, drugs, medical writing, gifts or other services Other financial or non-	lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options Receipt of equipment, materials, drugs, medical writing, gifts or other services Other financial or non- X_None

None.		

Please place an "X" next to the following statement to indicate your agreement:

Date	e:2022/8/:	16	
	r Name: Yin I		
			ancer in 2018 and their trends from 2010 to 2018 in Henan
	vince, China: Results from a		
Mai	nuscript number (if known)	·	
rela part to t	ted to the content of your i	manuscript. "Related" mean affected by the content of necessarily indicate a bias.	relationships/activities/interests listed below that are any relation with for-profit or not-for-profit third the manuscript. Disclosure represents a commitment f you are in doubt about whether to list a so.
	following questions apply the nuscript only.	to the author's relationship	s/activities/interests as they relate to the current
to t		ension, you should declare a	efined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive manuscript.
	em #1 below, report all sup time frame for disclosure is		in this manuscript without time limit. For all other items,
		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as	
		needed)	
		Time frame: Since the initial	planning of the work
1	All support for the present	XNone	
	manuscript (e.g., funding,		

Time frame: past 36 months

X_None

X_None

X_None

provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.

Grants or contracts from any entity (if not indicated

in item #1 above).

Consulting fees

Royalties or licenses

3

4

Payment or honoraria for	XNone	
lectures, presentations,		
speakers bureaus,		
	V Name	
•	x_None	
testimony		
	XNone	
meetings and/or travel		
	XNone	
pending		
Participation on a Data	XNone	
Safety Monitoring Board or		
Advisory Board		
Leadership or fiduciary role	X None	
1		
7		
	V None	
Stock or stock options	xNone	_
	XNone	
writing, gifts or other		
services		
Other financial or non-	XNone	
financial interests		
	speakers bureaus, manuscript writing or educational events Payment for expert testimony Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options Receipt of equipment, materials, drugs, medical writing, gifts or other services Other financial or non-	lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options Receipt of equipment, materials, drugs, medical writing, gifts or other services Other financial or non- X_None

None.		

Please place an "X" next to the following statement to indicate your agreement:

Province, China: Results from a provincial population-based cancer registry Manuscript number (if known): In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so. The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u> . The author's relationships/activities/interests should be <u>defined broadly</u> . For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript. In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months. Name all entities with whom you have this relationship or indicate none (add rows as needed) Name all entities with institution	Date	e:2022/8/1	.6	
In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so. The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u> . The author's relationships/activities/interests should be <u>defined broadly</u> . For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript. In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months. Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial planning of the work All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Time frame: past 36 months Time frame: past 36 months Time frame: past 36 months	You	r Name: Lanw	vei Guo	
related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so. The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only. The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript. In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months. Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial planning of the work All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Time frame: past 36 months Time frame: past 36 months	Prov	vince, China: Results from a	provincial population-bas	
manuscript only. The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript. In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months. Name all entities with whom you have this relationship or indicate none (add rows as needed)	relat part to tr	ted to the content of your n ies whose interests may be ansparency and does not n	nanuscript. "Related" mea affected by the content o ecessarily indicate a bias.	ans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a
to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript. In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months. Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial planning of the work All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Time frame: past 36 months Time frame: past 36 months			o the author's relationshi	ps/activities/interests as they relate to the <u>current</u>
Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial planning of the work All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Name all entities with whom you have this relations/Comments (e.g., if payments were made to you or to your institution) Time frame: Since the initial planning of the work X_None X_None	to th	ne epidemiology of hyperte	nsion, you should declare	all relationships with manufacturers of antihypertensive
whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial planning of the work All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Time frame: past 36 months A_None Time frame: past 36 months		-	=	d in this manuscript without time limit. For all other items,
whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial planning of the work All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Time frame: past 36 months A_None Time frame: past 36 months			Name all entities with	Specifications/Comments
none (add rows as needed) Time frame: Since the initial planning of the work All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Time frame: past 36 months 2 Grants or contracts from any entity (if not indicated			whom you have this	
Time frame: Since the initial planning of the work All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Time frame: past 36 months X_None Time frame: past 36 months			relationship or indicate	institution)
Time frame: Since the initial planning of the work All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Time frame: past 36 months 2 Grants or contracts from any entity (if not indicated			none (add rows as	
All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Time frame: past 36 months 2 Grants or contracts from any entity (if not indicated				
manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Time frame: past 36 months 2 Grants or contracts from any entity (if not indicated			Time frame: Since the initia	al planning of the work
provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Time frame: past 36 months 2 Grants or contracts from any entity (if not indicated	1		XNone	
medical writing, article processing charges, etc.) No time limit for this item. Time frame: past 36 months 2 Grants or contracts from any entity (if not indicated				
processing charges, etc.) No time limit for this item. Time frame: past 36 months 2 Grants or contracts from any entity (if not indicated				
No time limit for this item. Time frame: past 36 months Grants or contracts from any entity (if not indicated X_None				
Time frame: past 36 months 2 Grants or contracts from any entity (if not indicated				
2 Grants or contracts from any entity (if not indicatedXNone		No time innit for this item.		
2 Grants or contracts from any entity (if not indicatedX_None				
2 Grants or contracts from any entity (if not indicatedXNone			Time frame, nos	t 26 months
any entity (if not indicated	2	Grants or contracts from	1	t-50 months
	۷			
3 Royalties or licensesXNone	3	· · · · · · · · · · · · · · · · · · ·	X None	

4

Consulting fees

Payment or honoraria for	XNone	
lectures, presentations,		
speakers bureaus,		
	V Name	
•	x_None	
testimony		
	XNone	
meetings and/or travel		
	XNone	
pending		
Participation on a Data	XNone	
Safety Monitoring Board or		
Advisory Board		
Leadership or fiduciary role	X None	
1		
7		
	V None	
Stock or stock options	xNone	_
	XNone	
writing, gifts or other		
services		
Other financial or non-	XNone	
financial interests		
	speakers bureaus, manuscript writing or educational events Payment for expert testimony Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options Receipt of equipment, materials, drugs, medical writing, gifts or other services Other financial or non-	lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options Receipt of equipment, materials, drugs, medical writing, gifts or other services Other financial or non- X_None

None.		

Please place an "X" next to the following statement to indicate your agreement:

Dat	e:zuzz/8/1	.0	
You	r Name: Huifa	ing Xu	
Ma	nuscript Title: Incidence	e and mortality of gastric	cancer in 2018 and their trends from 2010 to 2018 in Hena
Pro	vince, China: Results from a	provincial population-bas	sed cancer registry
Ma	nuscript number (if known):		
rela par to t	ted to the content of your n ties whose interests may be	nanuscript. "Related" mea affected by the content o ecessarily indicate a bias.	relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a o so.
	following questions apply t	o the author's relationshi	ps/activities/interests as they relate to the <u>current</u>
to t		nsion, you should declare	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive
	·		·
	time frame for disclosure is	-	d in this manuscript without time limit. For all other items
		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as	
		needed)	
		Time frame: Since the initi	al planning of the work
1	All support for the present	XNone	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: pas	st 36 months
2	Grants or contracts from	XNone	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	X None	
	noyunces of heemses		

Consulting fees

Payment or honoraria for	XNone	
lectures, presentations,		
speakers bureaus,		
	V Name	
•	x_None	
testimony		
	XNone	
meetings and/or travel		
	XNone	
pending		
Participation on a Data	XNone	
Safety Monitoring Board or		
Advisory Board		
Leadership or fiduciary role	X None	
1		
7		
	V None	
Stock or stock options	xNone	_
Receipt of equipment,	XNone	
writing, gifts or other		
services		
Other financial or non-	XNone	
financial interests		
	speakers bureaus, manuscript writing or educational events Payment for expert testimony Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options Receipt of equipment, materials, drugs, medical writing, gifts or other services Other financial or non-	lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options Receipt of equipment, materials, drugs, medical writing, gifts or other services Other financial or non- X_None

None.		

Please place an "X" next to the following statement to indicate your agreement:

Your Name:	Date	e:2022/8/1	6	
Province, China: Results from a provincial population-based cancer registry	You	r Name: Hong	Wang	
In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so. The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only. The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript. In item #1 below, report all support for the work reported in this manuscript without time limit. For all other item the time frame for disclosure is the past 36 months. Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial planning of the work All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Time frame: Past 36 months Time frame: Past 36 months Time frame: Past 36 months Time frame: Past 36 months	Man	uscript Title: Incidence	and mortality of gastric	cancer in 2018 and their trends from 2010 to 2018 in Henan
In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so. The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only. The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript. In item #1 below, report all support for the work reported in this manuscript without time limit. For all other item the time frame for disclosure is the past 36 months. Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial planning of the work All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Time frame: past 36 months Time frame: past 36 months Time frame: past 36 months				sed cancer registry
related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so. The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only. The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript. In item #1 below, report all support for the work reported in this manuscript without time limit. For all other item the time frame for disclosure is the past 36 months. Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial planning of the work All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Time frame: past 36 months Time frame: past 36 months Time frame: past 36 months	Man	uscript number (if known):		
to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript. In item #1 below, report all support for the work reported in this manuscript without time limit. For all other item the time frame for disclosure is the past 36 months. Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial planning of the work All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	relate parte to trelate	ted to the content of your n ies whose interests may be ansparency and does not no tionship/activity/interest, it following questions apply t	nanuscript. "Related" me affected by the content o ecessarily indicate a bias. is preferable that you do	ans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment of the manuscript. Disclosure represents a commitment of the manuscript. If you are in doubt about whether to list a o so.
Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial planning of the work All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Time frame: past 36 months All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Time frame: past 36 months All support for the present manuscript (e.g., if payments were made to you or to your institution) Time frame: Since the initial planning of the work Time frame: Since the initial planning of the work All support for the present manuscript (e.g., if payments were made to you or to your institution)	to th med In ite	ne epidemiology of hyperter lication, even if that medica em #1 below, report all sup	nsion, you should declare tion is not mentioned in t port for the work reporte	all relationships with manufacturers of antihypertensive the manuscript.
whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial planning of the work 1 All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Time frame: past 36 months Z_None Time frame: past 36 months		inne name for alsolosare is	the past so months.	
Time frame: Since the initial planning of the work All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Time frame: past 36 months 2 Grants or contracts from any entity (if not indicated in item #1 above).			whom you have this relationship or indicate none (add rows as	(e.g., if payments were made to you or to your
manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Time frame: past 36 months 2 Grants or contracts from any entity (if not indicated in item #1 above).				al planning of the work
2 Grants or contracts from any entity (if not indicated in item #1 above)X_None	1	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	XNone	
2 Grants or contracts from any entity (if not indicated in item #1 above).				
2 Grants or contracts from any entity (if not indicated in item #1 above)X_None			Time frame: pag	st 36 months
in item #1 above).	2			
	3	· · · · · · · · · · · · · · · · · · ·	XNone	

Consulting fees

Payment or honoraria for	XNone	
lectures, presentations,		
speakers bureaus,		
	V Name	
•	x_None	
testimony		
	XNone	
meetings and/or travel		
	XNone	
pending		
Participation on a Data	XNone	
Safety Monitoring Board or		
Advisory Board		
Leadership or fiduciary role	X None	
1		
7		
	V None	
Stock or stock options	xNone	_
Receipt of equipment,	XNone	
writing, gifts or other		
services		
Other financial or non-	XNone	
financial interests		
	speakers bureaus, manuscript writing or educational events Payment for expert testimony Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options Receipt of equipment, materials, drugs, medical writing, gifts or other services Other financial or non-	lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options Receipt of equipment, materials, drugs, medical writing, gifts or other services Other financial or non- X_None

None.		

Please place an "X" next to the following statement to indicate your agreement:

Date	e:2022/8/1	.6	
You	r Name:Xiaoy	ang Wang	
Prov	nuscript Title: Incidence vince, China: Results from a nuscript number (if known):	provincial population-bas	cancer in 2018 and their trends from 2010 to 2018 in Henan ed cancer registry
rela part to ti	ted to the content of your n ies whose interests may be	nanuscript. "Related" mea affected by the content o ecessarily indicate a bias.	relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third f the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a so.
	following questions apply t nuscript only.	o the author's relationship	os/activities/interests as they relate to the current
to tl		nsion, you should declare	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive he manuscript.
	em #1 below, report all sup time frame for disclosure is	- · · · · · · · · · · · · · · · · · · ·	d in this manuscript without time limit. For all other items,
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
2	Grants or contracts from any entity (if not indicated in item #1 above).	Time frame: pasXNone	t 36 months

3

4

Royalties or licenses

Consulting fees

X__None

Payment or honoraria for	XNone	
lectures, presentations,		
speakers bureaus,		
	V Name	
•	x_None	
testimony		
	XNone	
meetings and/or travel		
	XNone	
pending		
Participation on a Data	XNone	
Safety Monitoring Board or		
Advisory Board		
Leadership or fiduciary role	X None	
1		
7		
	V None	
Stock or stock options	xNone	_
Receipt of equipment,	XNone	
writing, gifts or other		
services		
Other financial or non-	XNone	
financial interests		
	speakers bureaus, manuscript writing or educational events Payment for expert testimony Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options Receipt of equipment, materials, drugs, medical writing, gifts or other services Other financial or non-	lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options Receipt of equipment, materials, drugs, medical writing, gifts or other services Other financial or non- X_None

None.		

Please place an "X" next to the following statement to indicate your agreement:

Date	e:2022/8/1	6	
You	r Name: Luya	o Zhang	
Mar	nuscript Title: Incidence	and mortality of gastric c	ancer in 2018 and their trends from 2010 to 2018 in Henan
Prov	vince, China: Results from a	provincial population-base	ed cancer registry
Mar	nuscript number (if known):		
rela part to ti	ted to the content of your n ies whose interests may be	nanuscript. "Related" mea affected by the content of ecessarily indicate a bias.	relationships/activities/interests listed below that are ns any relation with for-profit or not-for-profit third the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a so.
	following questions apply touscript only.	o the author's relationship	os/activities/interests as they relate to the <u>current</u>
to ti		nsion, you should declare	lefined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive ne manuscript.
	em #1 below, report all sup time frame for disclosure is	-	l in this manuscript without time limit. For all other items,
		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as	
		needed)	
		Time frame: Since the initia	l planning of the work
1	All support for the present	XNone	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.) No time limit for this item.		
	No time minit for this item.		
		T:	26 months
2	Grants or contracts from	Time frame: past X None	56 MONUNS
۷	any entity (if not indicated	^NUITE	
	in item #1 above).		
3	Royalties or licenses	XNone	

4

Consulting fees

Payment or honoraria for	XNone	
lectures, presentations,		
speakers bureaus,		
	V Name	
•	x_None	
testimony		
	XNone	
meetings and/or travel		
	XNone	
pending		
Participation on a Data	XNone	
Safety Monitoring Board or		
Advisory Board		
Leadership or fiduciary role	X None	
1		
7		
	V None	
Stock or stock options	xNone	_
Receipt of equipment,	XNone	
writing, gifts or other		
services		
Other financial or non-	XNone	
financial interests		
	speakers bureaus, manuscript writing or educational events Payment for expert testimony Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options Receipt of equipment, materials, drugs, medical writing, gifts or other services Other financial or non-	lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options Receipt of equipment, materials, drugs, medical writing, gifts or other services Other financial or non- X_None

None.		

Please place an "X" next to the following statement to indicate your agreement:

Date	e:2022/8/1	6	
You	r Name: Shao	kai Zhang	
Mar	uscript Title: Incidence	and mortality of gastric c	ancer in 2018 and their trends from 2010 to 2018 in Henan
Prov	rince, China: Results from a	provincial population-base	ed cancer registry
Mar	uscript number (if known):		
		=	relationships/activities/interests listed below that are
	_	=	ns any relation with for-profit or not-for-profit third
			the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a
	tionship/activity/interest, it	-	
·Cia	nonsinp, activity, interest, is	is preferable that you do	50.
The	following questions apply t	o the author's relationship	s/activities/interests as they relate to the <u>current</u>
<u>man</u>	uscript only.		
	_	_	
		_	lefined broadly. For example, if your manuscript pertains
			all relationships with manufacturers of antihypertensive
med	ication, even if that medica	ition is not mentioned in ti	ne manuscript.
In it	em #1 helow report all sun	nort for the work reported	I in this manuscript without time limit. For all other items,
	time frame for disclosure is		ini this manuscript without time mint. For an other items,
tile	unie manie for disclosure is	the past 30 months.	
		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as needed)	
		Time frame: Since the initia	l planning of the work
1	All support for the present	X None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
2		Time frame: past	: 36 months
2	Grants or contracts from	XNone	
	any entity (if not indicated		
3	in item #1 above). Royalties or licenses	V None	
5	hoyalties of licenses	XNone	

4

Consulting fees

Payment or honoraria for	XNone	
lectures, presentations,		
speakers bureaus,		
	V Name	
•	x_None	
testimony		
	XNone	
meetings and/or travel		
Patents planned, issued or pending	XNone	
Participation on a Data Safety Monitoring Board or	XNone	
Advisory Board		
Leadership or fiduciary role	X None	
1		
· · · · · · · · · · · · · · · · · · ·		
	V None	
Stock or stock options	xNone	_
	XNone	
writing, gifts or other		
services		
Other financial or non- financial interests	XNone	
	speakers bureaus, manuscript writing or educational events Payment for expert testimony Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options Receipt of equipment, materials, drugs, medical writing, gifts or other services Other financial or non-	lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options Receipt of equipment, materials, drugs, medical writing, gifts or other services Other financial or non- X_None

None.		

Please place an "X" next to the following statement to indicate your agreement:

Date	e:2022/8/1	6	
	r Name: Binbi		
Prov	nuscript Title: Incidence vince, China: Results from a nuscript number (if known):	provincial population-base	ancer in 2018 and their trends from 2010 to 2018 in Henan ed cancer registry
relate part to trelate	ted to the content of your n ies whose interests may be ransparency and does not no tionship/activity/interest, it	nanuscript. "Related" mea affected by the content of ecessarily indicate a bias. is preferable that you do	relationships/activities/interests listed below that are ns any relation with for-profit or not-for-profit third f the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a so.
	uscript only.		
to the	ne epidemiology of hyperter lication, even if that medica	nsion, you should declare to the state of th	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive the manuscript. I in this manuscript without time limit. For all other items,
		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as	
		needed) Time frame: Since the initia	I planning of the week
1	All support for the present		i planning of the work
1	manuscript (e.g., funding,	XNone	
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	t 36 months
2	Grants or contracts from	X None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	XNone	

Consulting fees

Payment or honoraria for	XNone	
lectures, presentations,		
speakers bureaus,		
	V Name	
•	x_None	
testimony		
	XNone	
meetings and/or travel		
Patents planned, issued or pending	XNone	
Participation on a Data Safety Monitoring Board or	XNone	
Advisory Board		
Leadership or fiduciary role	X None	
1		
· · · · · · · · · · · · · · · · · · ·		
	V None	
Stock or stock options	xNone	_
	XNone	
writing, gifts or other		
services		
Other financial or non- financial interests	XNone	
	speakers bureaus, manuscript writing or educational events Payment for expert testimony Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options Receipt of equipment, materials, drugs, medical writing, gifts or other services Other financial or non-	lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options Receipt of equipment, materials, drugs, medical writing, gifts or other services Other financial or non- X_None

None.		

Please place an "X" next to the following statement to indicate your agreement: